德琪（浙江）医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China 2021-08-24 08:30
Antengene and MindRank AI Enter into Collaboration to Advance the Development of Difficult-to-Drug Molecular Targets 2021-08-09 08:30
Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma 2021-08-02 07:29
Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections 2021-07-26 08:44
Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma 2021-07-22 09:27
Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies 2021-07-14 10:00
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF) 2021-07-06 08:00
Antengene Provides an Update on Its Latest Developments 2021-06-18 14:10
Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS 2021-06-09 08:00
Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 2021-06-04 08:00
Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021 2021-06-02 08:00
Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021 2021-06-02 08:00
Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome 2021-05-28 08:00
Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development 2021-05-25 08:00
Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037) 2021-05-17 20:35
Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial 2021-05-17 08:00
Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China 2021-05-14 08:40
Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies 2021-05-14 08:00
Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer 2021-05-13 08:00
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines 2021-05-06 11:28
1 4 5 6 7 8 9